- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04805021
Hemofilia A Adquirida e Autoimunidade. Estudo de Populações de Linfócitos e Células Supressoras Derivadas de Mielóide (IMMUNHEMAC)
Acquired hemophilia A is a rare condition of hemostasis secondary to the development of antibodies against factor VIII. This is a potentially serious pathology that can be life-threatening due to the major risk of bleeding caused by the sometimes drastic decrease in the level of circulating factor VIII.
This pathology occurs overwhelmingly in elderly subjects or, more rarely, in young women, during the postpartum period. It appears idiopathic in 50% of cases and associated, for the other cases, with underlying pathologies such as autoimmune pathologies (rheumatoid arthritis and bullous pemphigoid in particular) and neoplasias, or with a particular circumstance represented by the post -partum.
The association between this autoimmune pathology and its association with pathologies of the same type or with circumstances involving the immune system, suggests that common mechanisms could favor its emergence.
This study therefore proposes to study lymphocyte populations and subpopulations as well as Myeloid-Derived Suppressor Cells and the cytokine profile, which are abnormal in a large part of autoimmune pathologies.
Visão geral do estudo
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Nantes, França
- CHU de Nantes
-
Saint-Nazaire, França
- CH de Saint Nazaire
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Patients with acquired hemophilia A will be recruited prospectively when diagnosed with acquired hemophilia A and will be followed in the study until recovery.
Patients with constitutional hemophilia A will be recruited prospectively. They should be over 50 years old and have severe or moderate hemophilia A, and not be taking any treatment that could interfere with the immune system or inflammatory markers.
Population of control subjects without coagulation abnormalities, over 60 years of age and not taking any treatment likely to interfere with the immune system or inflammatory markers.
Patient population with inflammatory pathology will include subjects with an inflammatory pathology likely, according to the literature, to be associated with acquired hemophilia A and, in particular patients with rheumatoid arthritis, if possible at diagnosis and not taking any treatment likely to interfere with the disease. immune system or inflammatory markers.
Descrição
Inclusion Criteria:
-
Patient population with acquired hemophilia A:
Adult patients with a diagnosis of acquired hemophilia A and with a social security system. Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
Obtaining signed and written informed consent for biocollection consent.
-
Population of Patients with constitutional hemophilia A:
Adult patients over 50 years of age with severe or moderate constitutional hemophilia A, with no history of autoimmune disease, and with a social security system.
Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
Obtaining signed and written informed consent for biocollection consent.
-
Population of control subjects:
Adult patients, over the age of 60, without a coagulation abnormality, with no history of autoimmune disease, and with a social security system.
Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
Obtaining signed and written informed consent for biocollection consent.
-
Patient population with inflammatory pathology:
Adult patients over the age of 50 with an inflammatory pathology likely to be associated with acquired hemophilia A, and with a social security system.
Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
Obtaining signed and written informed consent for biocollection consent.
Exclusion Criteria:
For the 4 groups:
- Minor patient, under guardianship or curatorship.
- Pregnant and lactating women.
- Blood transfusion less than 7 days old.
- Treatment with corticosteroids in the 7 days preceding inclusion or any other immunomodulatory or immunosuppressive treatment in the 4 weeks preceding inclusion.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: CASE_CONTROL
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Pacientes do grupo Hemofilia A Adquirida.
|
no intervention |
|
pacientes do grupo de hemofilia A constitucional.
|
no intervention |
|
pacientes do grupo de controle.
|
no intervention |
|
pacientes no grupo de pacientes com patologia inflamatória.
|
no intervention |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Evaluate the evolution of lymphocyte populations and subpopulations, MDSCs and inflammatory cytokines in patients with hemophilia A acquired at diagnosis and during follow-up
Prazo: 2 years
|
Comparisons between diagnosis and during follow-up |
2 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To test the link between the severity of the disease at diagnosis and the cellular and cytokine parameters.
Prazo: 2 years
|
Factor VIII level and inhibitor titration at diagnosis |
2 years
|
|
Comparisons of baseline lymphocyte and cytokine data between patients with a favorable versus unfavorable final diagnosis.
Prazo: 2 years
|
Cell populations and cytokine profile and half-life of the inhibitor under treatment, time before normalization of the Factor VIII / Willebrand factor ratio, total duration of treatment with corticosteroids, recurrence and mortality tested to define a favorable course of the disease or unfavorable. |
2 years
|
|
Comparison of lymphocyte populations and subpopulations, MDSCs and inflammatory cytokines between different groups.
Prazo: 2 years
|
Cell populations and cytokine profile of the different groups at diagnosis and at the end of follow-up. |
2 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Marc Fouassier, Nantes University Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- RC20_0253
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .